

# Clinical trials of 3 months DAPT

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 stent

Trial	Treatments	Patients	Trials design and methods
<b>3 months DAPT vs 12 months DAPT</b>			
<a href="#">OPTIMIZE , 2013</a> [NCT01113372] n=1563/1556 follow-up:	3 months DAPT (aspirin (100-200 mg daily) and clopidogrel (75 mg daily)) versus 12 months DAPT	patients with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents	Parallel groups open-label Brazil

More details and results :

- dual antiplatelet therapy for stent in all type of patients at <http://www.trialresultscenter.org/go-Q578>

## References

### OPTIMIZE, 2013:

Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicoleta EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmo M, Staico R, Costa JR Jr, de Ca Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-22 [[24177257](#)] [10.1001/jama.2013.282183](https://doi.org/10.1001/jama.2013.282183)

## 2 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
<b>3 months DAPT vs 12 months DAPT</b>			
<a href="#">OPTIMIZE , 2013</a> [NCT01113372] n=1563/1556 follow-up:	3 months DAPT (aspirin (100-200 mg daily) and clopidogrel (75 mg daily)) versus 12 months DAPT	patients with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents	Parallel groups open-label Brazil

More details and results :

- antiplatelets drug for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q389>

## References

### **OPTIMIZE, 2013:**

Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmo M, Staico R, Costa JR Jr, de Ca Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-22 [[24177257](#)] [10.1001/jama.2013.282183](#)